Alabama Department of Public Health (ADPH)
Alabama Emergency Response Technology (ALERT)
Health Alert Network (HAN)
December 2, 2022

Bebtelovimab Not Authorized in U.S. for Current SAR-CoV-2 Subvariants

On November 30, 2022, the Food and Drug Administration (FDA) announced that bebtelovimab is not currently authorized for emergency use to treat COVID-19 because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1, which are the predominant SARS-CoV-2 variants in the United States.

Providers are asked to continue to store any remaining bebtelovimab vials appropriately in case the product can be used to treat future variants. The updated bebtelovimab fact sheet can be found at https://www.fda.gov/media/156152/download. Full information regarding this change can be found at https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region

Paxlovid, Veklury, and Lagevrio are expected to retain activity against BQ.1 and BQ.1.1. For additional information concerning COVID 19 therapeutics, please visit links from the Infectious Disease Society of America, the CDC, National Institutes of Health, and ASPR.

https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/

https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-omicron-subvariants/

https://www.covid19treatmentguidelines.nih.gov/

https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/default.aspx